Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer